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Background: ANCA-associated vasculitis (AAV) with renal involvement is not uncommon in older individuals.
Unfortunately, this can be catastrophic requiring hemodialysis (HD) and may lead to end stage renal disease (ESRD).
However, more than 50 % of patients with AAV who require HD initially have renal recovery and discontinue HD.
The aim of this study was to describe a retrospective cohort of older patients with AAV and severe renal involvement
which required hemodialysis.
Methods: Between 1995 and 2013 a total of 30 patients with histologic evidence of pauci-immune glomerulonephritis
who required HD were evaluated at a single university center. The association of demographic and clinical parameters
with age was assessed. Older age of disease onset was defined as age ≥60 years. The risk of developing ESRD at 3
months was examined using univariate logistic regression analysis.
Results: Among 30 patients with AAV who required HD, the mean age of disease onset was 59 ± 17 years (range
22-88 years). Twelve patients were in the older age group, and 18 were in the younger group. Three months after
diagnosis, 43 % of the cohort had ESRD with a statistically similar proportion of older (n = 9, 50 %) versus younger
(n = 4, 33 %) patients (p = 0.367). Most patients (93 %) received immunosuppressive therapy. There was not a
statistically significant association between age and ESRD.
Conclusions: These data suggest that age alone does not predict renal recovery among individuals on HD due to
AAV. Renal recovery is a realistic expectation and outcome, if patients are treated, even among older patients with
AAV who require HD initially.
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The population of the United States is aging. It is antici-
pated that the population of Americans aged 65 years or
older will double during the next 25 years to about 72
million [1]. Although ANCA-associated vasculitis (AAV)
is rare in the general population, epidemiologic data
demonstrate that it has a predilection for older individuals
with some studies citing a peak incidence in the 65–74
year age group [2, 3]. Therefore, it is expected that this
demographic will be increasing in the very near future.* Correspondence: rmanno3@jhmi.edu
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creativecommons.org/publicdomain/zero/1.0/Renal involvement in AAV is common and can be se-
vere requiring renal replacement therapy [4]. This has im-
portant implications as severe renal dysfunction in AAV is
associated with poor survival and increased risk for
progression to end stage renal disease (ESRD) [5, 6]. The
combination of older age and severe renal involvement
from AAV portends a particularly grim outcome [7–10].
It is well established that without treatment AAV leads
to considerable morbidity and mortality. Conversely, if
treatment is appropriately initiated, less than 40 % of
patients who present with severe kidney failure from
AAV which requires hemodialysis will remain dialysis
dependent [11]. Recent data have demonstrated that al-
though low baseline glomerular filtration rate (GFR) and
high burden of renal scar on biopsy are associated withrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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Manno et al. BMC Nephrology  (2015) 16:88 Page 2 of 5decreased treatment response rates, there is no identifi-
able GFR cutoff or clear pathologic finding where treat-
ment would be considered futile [11–13]. However, the
potential toxicities of immunosuppressive therapy, such
as infection, cytopenias and drug interactions can be
daunting when considering treatment for an older pa-
tient with severe AAV renal disease on hemodialysis.
This vulnerable population may be particularly suscep-
tible to the adverse effects of therapy.
Histopathologic classification of glomerulonephritis in
AAV has emerged as a potential predictor of long-term
renal outcomes [13]. However, recent data has ques-
tioned if histologic class alone provides additional clinic-
ally useful information beyond established predictive
parameters, such as age, baseline GFR and degree of
tubular atrophy [14].
The aim of this study was to describe a retrospective
cohort of older patients with AAV and severe renal in-
volvement which required hemodialysis. A younger co-
hort of patients with AAV and severe renal involvement
was included for comparison.
Methods
Study population
Potential patients for this study were identified from a
pathology database (1995–2013) using the term “pauci-
immune glomerulonephritis.” To be included in the
study, individuals had to have a pathologic (kidney bi-
opsy) and clinical diagnosis of AAV.
AAV was defined as granulomatosis with polyangiitis
(GPA) or microscopic polyangiitis (MPA). Patients had
to require hemodialysis at the time of kidney biopsy and
were followed for at least twelve months after biopsy.
This study protocol was approved by the Johns Hopkins
Office of Human Subjects Research and Institutional
Review Board. Since this was a retrospective observa-
tional study for the generation of a de-identified data
set, written informed consent of each participant was
not required.
Acquisition of clinical and laboratory data
Patient demographics, clinical features at the time of
diagnosis (including age), treatment regimens, hemodialysis
duration, laboratory data and outcomes were abstracted
retrospectively from the medical record.
Definitions
Patients were classified as having GPA or MPA based on
the Chapel Hill Consensus Conference Criteria [15]. Age
at the time of diagnosis was determined from the med-
ical record, and late-age onset AAV was defined as the
onset of disease at age 60 years or older. The outcome
of ESRD was defined as the need for continued dialysis
for more than 3 months. Late ESRD was defined as theresumption of renal replacement therapy after discontinu-
ation of hemodialysis within the first three months. Renal
recovery was defined as the discontinuation of hemodialysis
for any period of time as documented by the treating phys-
ician in the medical record. Renal histopathology was
grouped into four classes based on criteria used by the
International Working Group of Renal Pathologists [13]:
Focal (≥50 % normal glomeruli), Crescentic (≥50 % glom-
eruli with cellular crescents), Mixed (<50 % normal, <50 %
crescentic, <50 % globally sclerotic glomeruli), and Sclerotic
(≥50 % globally sclerotic glomeruli).
Statistical analysis
Continuous, normally distributed variables were summa-
rized as mean value ± standard deviation. Discrete vari-
ables were summarized as proportions. Differences in
means between the older and younger cohorts were evalu-
ated using non-parametric tests for continuous variables
(Wilcoxon-Mann-Whitney). Differences in proportions
between cohorts were evaluated with Chi-square test for
discrete variables. Logistic regression was used to calculate
odds ratios and determine the risk of ESRD as a function
of age at diagnosis. Age was modeled as a continuous vari-
able, dichotomous variable (cut-off ≥60 years) and by
tertiles (<60 years, 60–69 years, ≥70 years). Statistical ana-
lyses were performed using Stata IC 10.0. P-values are two
sided with α = 0.05.
Results
The baseline characteristics of the 30 patients who met
inclusion criteria for this study are presented in Table 1.
The mean age of AAV onset among the cohort was 59 ±
17 years (range 22 to 88 years). Eighteen patients (60 %)
had late-age onset AAV, defined as disease onset at age
60 years or greater. Of those with late-age onset AAV,
10 (56 %) had disease onset between ages 60 and
70 years, 6 (33 %) had disease onset between 71 and
79 years, and 2 (11 %) had onset after age 80. The ma-
jority of the cohort had a new diagnosis of AAV (n = 26,
87 %). Among those with relapsing disease (n = 4), 3
patients were in the late-age onset group.
All of the patients had severe renal involvement at
presentation requiring hemodialysis. The mean peak cre-
atinine was higher among those with late-age onset AAV
(8.2 ± 4.4, older vs 5.8 ± 2.5 mg/dL, younger; p = 0.150),
although this did not reach statistical significance. The
histopathologic classes were similarly distributed between
the older and younger vasculitis patients, with half of the
patients in each age group with Mixed pathology. Both
older and younger patients had similar percentage of
normal glomeruli on biopsy.
All 30 patients in this cohort had some extra-renal
manifestation of vasculitis. An equal proportion of pa-
tients in the older (72 %) vs the younger (75 %) age
Table 1 Baseline characteristics of patients with ANCA-associated vasculitis who required hemodialysis at the time of kidney biopsy
stratified by age of vasculitis diagnosis
Age of onset < 60 years (n = 12) Age of onset≥ 60 years (n = 18) p-value
Age at diagnosis, years (mean ± SDa) 41 ± 11 71 ± 7 <0.001
Female 8 (67 %) 7 (39 %) 0.136
African-American 4 (30 %) 2 (11 %) 0.136
Diagnosis
Granulomatosis with polyangiitis 8 (67 %) 10 (56 %) 0.543
Microscopic polyangiitis 4 (33 %) 8 (44 %)
PR3-ANCA positiveb 6 (67 %) 8 (50 %) 0.420
MPO-ANCA positiveb 3 (33 %) 8 (50 %)
Peak serum creatinine, mg/dL (mean ± SDa) 5.8 ± 2.5 8.2 ± 4.4 0.150
Normal glomeruli, % (mean ± SDa) 21.5 ± 18.1 27.4 ± 23.8 0.432
Renal histopathologic class
Crescentic 4 (34 %) 4 (22 %)
Focal 1 (8 %) 3 (17 %)
Mixed 6 (50 %) 9 (50 %)
Sclerotic 1 (8 %) 2 (11 %)
aSD standard deviation
bData analyzed from 25 individuals who were ANCA positive
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(p = 0.866), although few had respiratory failure (17 %
older vs 22 % younger, p = 0.709). Fewer older patients
(28 %) had inflammatory arthritis attributed to vasculitis
at presentation compared to younger patients (58 %)
and no patients with AAV onset after at 70 years had in-
flammatory arthritis at the time of presentation.
All 30 patients in the cohort were treated with cortico-
steroids initially with the majority (87 %) receiving intra-
venous methylprednisolone. Two patients, both in the
late-age onset group, received corticosteroid monother-
apy. These two patients had Sclerotic class biopsies
without extra-renal disease. In addition, both of these
patients were treated at outside facilities and were seen
for a second opinion at this tertiary care center.
All (n = 12, 100 %) of the younger patients received
cyclophosphamide therapy compared to only 78 % of the
older patients. Cyclophosphamide was administered or-
ally among the majority who received it (83 %). Among
the older patients, 5 % were treated with rituximab and
5 % were treated with mycophenolate mofetil. All pa-
tients over the age of 70 years were treated with cyclo-
phosphamide, except for the oldest patient in the cohort
(88 years old) who was the sole recipient of mycopheno-
late mofetil. A similar proportion of older (28 %) and
younger (17 %) patients also received adjuvant plasma-
pheresis at that time of diagnosis (p = 0.481).
Three months after diagnosis, 43 % of the cohort had
ESRD with an equal proportion of older (n = 9, 50 %) vs
younger (n = 4, 33 %) patients (p = 0.367). One patient had
late ESRD with onset 4 months after diagnosis. Thispatient was in the younger age group (age 27 years). Con-
versely, 67 % of the younger cohort (age onset <60 years)
had renal recovery and discontinued hemodialysis within
the first 3 months after diagnosis. Similarly, 50 % of those
age 60–70 years and 50 % of those age ≥70 also discontin-
ued hemodialysis and had renal recovery. This included
the oldest patient in the cohort (age 88 years) who had
complete renal recovery and discontinued hemodialysis.
The two patients who received corticosteroid mono-
therapy (both in the late-age onset AAV group) had
ESRD and no renal recovery. Among patients treated
with cyclophosphamide, 42 % had ESRD. Both patients
treated with mycophenolate mofetil and rituximab had
renal recovery at three months and were in the late-age
onset AAV group.
Within the 12-months of follow up after biopsy, there
were two deaths. Both deaths were in the late-age onset
group (ages 65 and 69 years). There were no deaths in
the first year of follow up in the younger age onset
group.
There was no statistically significant association be-
tween age and ESRD in univariate logistic regression
models. With age modeled as a continuous variable
there was not an increased risk of ESRD for a one year
increase in age of AAV onset (OR 1.01, p = 0.677). When
comparing patients with disease onset younger than age
60 to those older (age as a binary variable), there was a
trend for an increased risk of ESRD among the older pa-
tients (OR 1.55, p = 0.370), but this did not reach statis-
tical significance. Similarly, there was a trend for an
increased risk of ESRD among the oldest patients with
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(<60 years), OR 1.87 (p = 0.459).
Discussion
There is relatively little information on the clinical fea-
tures and outcomes of older individuals with AAV on
hemodialysis. Our study suggests that age alone does not
predict renal recovery among individuals on hemodialysis
due to AAV. The majority of patients in our cohort re-
ceived treatment with aggressive immunosuppressive
therapy, which is necessary for renal recovery, regard-
less of age.
Previous reports which have examined AAV in older
populations have not focused specifically on elderly who
required hemodialysis at presentation. Bomback, et al.
described the clinical course of 78 patients over the age
of 80 years who had biopsy proven pauci-immune glom-
erulonephritis but did not necessarily require renal re-
placement therapy at diagnosis (mean creatinine at
biopsy 4.3 ± 2.5 mg/dl) [16]. They found peak serum cre-
atinine and use of immunosuppressive therapy influ-
enced progression to ESRD and that the highest risk of
morbidity and mortality for these elderly patients was
within the first six months after diagnosis, which sug-
gests that the benefit of immunosuppressive therapy is
early in the disease [16]. Similarly, in our cohort, pa-
tients who received steroid monotherapy, without an
additional immunosuppressive agent, did not have any
renal recovery.
De Lind van Wijngaarden, et al. prospectively followed
69 patients with AAV who required hemodialysis at the
time of diagnosis and evaluated if the hazards of immuno-
suppressive treatment outweigh expectations of recovery
[12]. The mean age of the cohort was 64 years (range 26
to 78). The authors did not focus on age as a predictor in
their models, but they found the chance of renal recovery
among patients with AAV on hemodialysis was best pre-
dicted by type of adjunctive treatment and histopathologic
findings. However, even with ominous biopsy features
the chance of renal recovery exceeded the chance of
therapy-related death if treatment includes plasma ex-
change [12]. Another study of 155 patients with AAV
and severe kidney involvement (GFR < 15 mgl/min per
1.73 m2) similarly found that although poor renal func-
tion at diagnosis was associated with lower treatment
response rate, there was not a “futility” threshold below
which the risk of therapy would universally outweigh
potential benefits [11].
A study of Chinese patients with AAV on hemodialysis
at the time of diagnosis found that 50 % of patients pro-
gressed to ESRD [17], which is similar to the findings in
our study (46 % patients with ESRD at 6 months). The
mean age of this cohort was 57 ± 16 years (range 14 to
83), and they found that older age was associated withincreased risk of all-cause and therapy-related mortality
but age alone (by one year increments) was not associ-
ated with dialysis independence [17].
In our single center experience, which was limited by
retrospective design and small sample size, 57 % of pa-
tients who required hemodialysis at the time of diagnosis
due to AAV had renal recovery. Among the oldest pa-
tients in the cohort, 50 % achieved renal recovery, in-
cluding the oldest patient who was age 88. Similar to the
previously published reports, renal recovery in our co-
hort only occurred in the context of treatment. The two
patients who did not receive treatment beyond cortico-
steroids presumably had additional immunosuppressive
therapy held because of their age and kidney biopsy class
(Sclerotic). As discussed, age should not be a deciding
factor in determining treatment, because even the oldest
patient in our cohort was able to achieve renal recovery
with appropriate therapy. Regarding the biopsy findings
in these two patients (Sclerotic) recent data has demon-
strated that even with severe renal scarring there is no
“futility” threshold which can be identified for therapy
[11]. The unfortunate management of these two patients
demonstrates “real world” practices. Hence, the import-
ance of our study, albeit small, to demonstrate success
and renal recovery even among our oldest patients when
proper treatment was administered.
Less than one-third of our total cohort received adjuvant
plasmapheresis, which remains a controversial part of man-
agement for AAV with severe renal failure in the absence of
alveolar hemorrhage in the United States [18, 19]. As more
data has emerged recently about the benefits of this therapy
in combination with immunosuppression in severe AAV,
plasmapheresis is being used with a greater frequency today
than was seen during the study period of our cohort. Future
studies investigating the effectiveness of plasmapheresis
for AAV should include older individuals to assess if there
is a particular benefit for this vulnerable population.
Although nearly all patients in this cohort received
cyclophosphamide, the optimal induction regimen and
dose for older patients with AAV still requires further
study. Rituximab was not yet FDA approved during a
majority of our study period which is indicated by majority
of patients receiving cyclophosphamide. However, cyclo-
phosphamide dosing issues and drug-induced cytopenias
are significant concerns for older patients, and the potential
benefit of rituximab over cyclophosphamide for the treat-
ment of older individuals with AAV should be explored.
The approach to management of older patients may
be ‘less is more’ when there are concerns that the side
effects and toxicities of therapy may be worse than the
disease itself. The decision to treat an older patient who
has already suffered a major complication from AAV,
such as renal failure requiring dialysis, is a challenging
one. Without treatment, inevitably the patient will be
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ESRD is inescapable. However, these data show that
renal recovery can occur, even among the oldest patients
with AAV. Older age and severe renal involvement are
predictors of the most ominous outcomes from AAV,
and yet renal recovery is still a realistic expectation for
this population.
Conclusions
In summary, these data support that renal recovery is a
realistic expectation and outcome among older patients
who require HD initially. Age alone is not an accurate
predictor of late or definitive ESRD nor is treatment
with steroids monotherapy sufficient. We recognize the
small sample size of this study and retrospective design
as limitations. However, these data provide important
insight into some of the complexities physicians are
faced with in the management of these very sick pa-
tients. Our study has value as a sample of “real world”
practices, experiences, and outcomes outside of the
clinical trial setting.
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